指南与共识乳腺癌放疗放疗物理与技术

ATM基因变异乳腺癌患者:乳腺放疗推荐意见

ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.
指南 / 共识 · Int J Radiat Oncol Biol Phys · 2021-02-03

本文通过文献检索与专家小组讨论,评估携带胚系ATM变异的乳腺癌患者接受乳腺放疗后的毒性及对侧乳腺癌风险。结论认为,对大多数携带ATM变异的乳腺癌患者,辅助放疗是安全的;但c.5557G>A(rs1801516)变异者及携带特定罕见有害错义变异的45岁以下女性可能风险较高,应充分告知并尽量降低对侧乳腺剂量。

要点

  • 大多数携带ATM变异的乳腺癌患者接受辅助放疗是安全的。
  • c.5557G>A(rs1801516)变异者放疗后急性和晚期不良反应风险可能轻度增加。
  • 45岁以下携带特定罕见有害ATM错义变异者,放疗后对侧乳腺癌风险可能较高。

核心结论

  • 对大多数携带ATM变异的乳腺癌患者,辅助放疗是安全的。
  • c.5557G>A(rs1801516)变异者及45岁以下携带特定罕见有害ATM错义变异者可能风险较高,应告知并尽量降低对侧乳腺剂量。

研究设计与样本

  • 通过PubMed文献检索评估胚系ATM变异状态与乳腺放疗后毒性风险的关联。
  • 由乳腺放射肿瘤学家、遗传咨询师和基础科学家组成专家小组,审查ATM变异与放疗诱导毒性或第二恶性肿瘤风险的关联及其对乳腺放疗推荐的影响。

主要发现

  • ATM致病性变异携带者发生乳腺癌的风险增加2至4倍。
  • ATM变异总体上不持续增加放疗后毒性风险,但c.5557G>A(rs1801516)单核苷酸变异者急性和晚期放疗效应风险可能轻度增加。
  • 大多数携带ATM变异的乳腺癌患者放疗后5年发生对侧乳腺癌的绝对超额风险极低。
  • 45岁以下携带罕见有害ATM错义变异的女性,随时间推移发生放疗诱导的对侧乳腺癌风险可能较高。

关键数值与推荐

  • ATM致病性变异携带者乳腺癌风险增加2至4倍。
  • c.5557G>A(rs1801516)变异者放疗后急性和晚期效应风险可能轻度增加。
  • 大多数ATM变异患者放疗后5年对侧乳腺癌绝对超额风险极低。

临床怎么用

  • 对大多数携带ATM变异的乳腺癌患者,可安全实施辅助放疗。
  • 对c.5557G>A(rs1801516)变异者及45岁以下携带特定罕见有害ATM错义变异者,应告知对侧乳腺癌潜在风险。
  • 对此类高风险患者,应尽一切努力最小化对侧乳腺剂量。

局限性

  • 已发表数据不一致,限制了精确推荐的形成。
  • 需要进一步开展前瞻性研究,并建立集中数据库记录放疗结局与遗传状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Advances in germline genetic testing have led to a surge in identification of ataxia-telangiectasia mutated (ATM) variant carriers among breast cancer patients, raising numerous questions regarding use of breast radiation therapy (RT) in this population. METHODS: A literature search using PubMed identified articles assessing association(s) between the germline ATM variant status and the risk of toxicity after breast RT. An expert panel of breast radiation oncologists, genetic counselors, and basic scientists convened to review the association between ATM variants and radiation-induced toxicity or secondary malignancy risk and to determine any impact on breast RT recommendations. RESULTS: Carriers of pathogenic variants in ATM have a 2- to 4-fold increased risk for developing breast cancer. ATM variants do not consistently increase risks of toxicities after RT, except possibly among patients with the single nucleotide variant c5557G>A (rs1801516), in whom a small increased risk for the development of both acute and late radiation effects has been identified. In most breast cancer patients with ATM variants, the excess 5-year absolute risk of developing a secondary contralateral breast cancer (CBC) after radiation is extremely low. The exception is in women younger than 45 years old with deleterious rare ATM missense variants, who may be at higher risk for developing a radiation-induced CBC over time. CONCLUSIONS: Adjuvant radiation is safe for most breast cancer patients who harbor ATM variants. The possible exceptions are patients with the variant c5557G>A (rs1801516) and patients younger than 45 years old with certain rare deleterious ATM variants, who may be at higher risk for developing CBC. These latter patients should be counseled regarding this potential risk, and every effort should be made to minimize the contralateral breast dose. However, the inconsistency of published data limits precise recommendations, magnifying the need for further prospective studies and the development of a centralized database cataloging RT outcomes and genetic status.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. McDuff SGR, Bellon JR, Shannon KM, et al. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations. Int J Radiat Oncol Biol Phys. 2021. PMID: 33545302. doi:10.1016/j.ijrobp.2021.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。